Trinity Biotech (NASDAQ:TRIB) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a note issued to investors on Thursday. The firm set a “buy” rating on the stock.

Trinity Biotech Price Performance

Shares of TRIB opened at $1.75 on Thursday. The firm’s 50 day simple moving average is $2.00 and its 200 day simple moving average is $2.22. The company has a market capitalization of $13.34 million, a P/E ratio of -0.55 and a beta of 1.24. Trinity Biotech has a 1-year low of $1.75 and a 1-year high of $5.50.

Trinity Biotech (NASDAQ:TRIB) last posted its quarterly earnings results on Thursday, April 4th. The company reported ($0.68) EPS for the quarter. The business had revenue of $13.43 million for the quarter. On average, equities analysts anticipate that Trinity Biotech will post -1.5 earnings per share for the current year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.